Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
- 29 July 2022
- journal article
- review article
- Published by Springer Science and Business Media LLC in Psychopharmacology
- Vol. 239 (9), 2713-2734
- https://doi.org/10.1007/s00213-022-06196-4
Abstract
Rationale Autism spectrum disorder (ASD) is defined as a group of neurodevelopmental disorders whose symptoms include impaired communication and social interaction, restricted and repetitive patterns of behavior, and varying levels of intellectual disability. ASD is observed in early childhood and is one of the most severe chronic childhood disorders in prevalence, morbidity, and impact on society. It is usually accompanied by attention deficit hyperactivity disorder, anxiety, depression, sleep disorders, and epilepsy. The treatment of ASD has low efficacy, possibly because it has a heterogeneous nature, and its neurobiological basis is not clearly understood. Drugs such as risperidone and aripiprazole are the only two drugs available that are recognized by the Food and Drug Administration, primarily for treating the behavioral symptoms of this disorder. These drugs have limited efficacy and a high potential for inducing undesirable effects, compromising treatment adherence. Therefore, there is great interest in exploring the endocannabinoid system, which modulates the activity of other neurotransmitters, has actions in social behavior and seems to be altered in patients with ASD. Thus, cannabidiol (CBD) emerges as a possible strategy for treating ASD symptoms since it has relevant pharmacological actions on the endocannabinoid system and shows promising results in studies related to disorders in the central nervous system. Objectives Review the preclinical and clinical data supporting CBD’s potential as a treatment for the symptoms and comorbidities associated with ASD, as well as discuss and provide information with the purpose of not trivializing the use of this drug.This publication has 218 references indexed in Scilit:
- Persistent cannabis users show neuropsychological decline from childhood to midlifeProceedings of the National Academy of Sciences of the United States of America, 2012
- The social motivation theory of autismTrends in Cognitive Sciences, 2012
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophreniaTranslational Psychiatry, 2012
- Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia PatientsNeuropsychopharmacology, 2011
- CB1 Cannabinoid Receptors Increase Neuronal Precursor Proliferation through AKT/Glycogen Synthase Kinase-3β/β-Catenin SignalingOnline Journal of Public Health Informatics, 2010
- Differential monocyte responses to TLR ligands in children with autism spectrum disordersBrain, Behavior, and Immunity, 2010
- Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and PsychopathologyNeuropsychopharmacology, 2009
- Common circuit defect of excitatory-inhibitory balance in mouse models of autismJournal of Neurodevelopmental Disorders, 2009
- Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitroBritish Journal of Pharmacology, 2007
- Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppressionProceedings of the National Academy of Sciences of the United States of America, 2006